A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
Statistics in Medicine · 2025
DOI: 10.1002/sim.70103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Yuan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Precision Medicine, Clinical Trials, Phase II as Topic, Research Design, Clinical Trials, Phase III as Topic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Dr. Mien-Chie Hung and Mrs. Kinglan Hung Endowed Professorship of MD Anderson Cancer Center, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Targeted cancer therapies aim to effectively treat patients with specific biomarker profiles. Nevertheless, these therapies may not always precisely hit their intended targets, leading to uncertainty about the specific subset of patients who will benefit. To address this uncertainty, the identification of sensitive patient subsets in clinical trials becomes crucial. Our proposed phase IIB/III clinical trial design seeks to pinpoint a biomarker signature with precision, ensuring the accurate identification of patients who will respond to a specific treatment. This approach allows for the selective enrollment of sensitive patients to maximize benefits for trial participants. We incorporate Bayesian methodology to facilitate response‐adaptive randomization, enhancing the likelihood that each participant receives his/her optimal treatment. Furthermore, our design uses inverse‐probability‐of‐treatment‐weighted analysis to avoid selection bias and control for the type I error rate. The evaluation of this trial design is based on four criteria: the statistical power, response rate of all patients participating in the current trial, their individual loss, and probabilities of receiving their optimal treatment for both current trial participants and future patients. Simulations demonstrate the proposed design's potential for maximizing trial participants' benefits with little sacrifice on statistical power. Its key advantages include an improved overall response rate within the trial and a higher percentage of patients receiving the optimal treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Biometrics, Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
- Department of Epidemiology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Yuan Li, Ruosha Li, Xuelin Huang, Jing Ning
Förderung
- Dr. Mien-Chie Hung and Mrs. Kinglan Hung Endowed Professorship of MD Anderson Cancer Center
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Li, Y., Lai, D., Li, R., Chen, H., Huang, X., & Ning, J. (2025). A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine. Statistics in Medicine. https://doi.org/10.1002/sim.70103
Vancouver
Li Y, Lai D, Li R, Chen H, Huang X, Ning J. A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine. Statistics in Medicine. 2025. doi:10.1002/sim.70103
BibTeX
@article{Li2025,
author = {Li, Yuan and Lai, Dejian and Li, Ruosha and Chen, Han and Huang, Xuelin and Ning, Jing},
title = {A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70103}
}
EUVIMED